TYROSINE AND C-KINASE ACTIVITY AND PI TURNOVER IN T-CELL
TYROSINE AND C-KINASE ACTIVITY AND PI TURNOVER IN T-CELL
批准号:
3299795
负责人:
Andre Elias Nel
金额:
$10.13万
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-09-01 至 1991-08-31
关键词:
T lymphocyte adenylate cyclase calcium complementary DNA flow cytometry gel electrophoresis guanine nucleotide binding protein human tissue immunoprecipitation inositol phosphates interleukin 2 laboratory rabbit lectin leukocyte activation /transformation membrane lipids monoclonal antibody phosphatidylinositols phospholipase C phosphorylation protein kinase C protein tyrosine kinase receptor
中文摘要
T淋巴细胞可通过CD 2和CD 3受体活化
通过使用特异性M.Ab和促有丝分裂凝集素。 一系列
第二信使需要为随后的
通过分泌IL-2和表达
它的受体。 长期目标是了解
磷脂代谢、C-激酶活性与细胞
CA+2沿着这些激活途径与视图来定义
疾病反应调整的目标区域。 一个
对这些机制的理解也可以解释
某些免疫缺陷的病理生理基础。
因此,具体目标是使用M.Ab和促有丝分裂凝集素
以确定C-激酶和CA+2 i.t.o. I1-2
受体表达,底物磷酸化,受体
调节和表达c-fos、c-myc、IL-2、
γ-IFN和IL-2受体。 这些研究还将着眼于
一些先于C激酶活化的过程,
即PI周转、IP 3、释放、CA+2通量和受体
聚合来 这可能揭示了效力的差异,
第二信使产生,例如在凝集素之间
和抗T3 M. Ab。 化学调节剂/药物对
这些过程也将得到审查。 信号转导作用
受体相关的G-结合蛋白将在
它们刺激腺苷酸环化酶
和磷脂酶C活性。 In vivo的重要性
自磷酸化、易位和蛋白水解激活
将讨论C激酶。 最后,重要的互动
C-激酶和酪氨酸激酶pp 56 Tck将用
以了解膜之间的可能联系
磷脂代谢和促有丝分裂事件。
为了进行这些研究,
已经发展了:蛋白质磷酸化研究,
特异性磷酸化底物的免疫沉淀
PAGE和放射自显影,磷酸化氨基酸分析,
磷脂提取物,离子交换色谱法测定
IP 3释放和mRNA的细胞质斑点印迹分析。 完整
通过流式细胞术,3 H-Td摄取,
IL-2分泌和Quin 2荧光。
英文摘要
T-lymphocytes can be activated via the CD2 and CD3 receptors
through the use of specific M.Ab and mitogenic lectins. A host of
second messengers are required to set the stage for subsequent
autocrine proliferation through secretion of IL-2 and expression of
its receptor. The long term objective is an understanding of the
importance of phospholipid metabolism, C-kinase activity and cell
CA+2 along these activation pathways with the view to define
target areas for response modification in disease. An
understanding of these mechanisms may also explain the
pathophysiological basic of certain immuno-deficiencies.
The specific aims are therefore to use M.Ab and mitogenic lectins
to define the cell biological role of C-kinase and CA+2 i.t.o. I1-2
receptor expression, substrate phos-phorylation, receptor
modulation and expression of mRNA for c-fos, c-myc, IL-2,
gamma-IFN, and the IL-2 receptor. These studies will also look at
some of the processes which precedes the activation of C-kinase,
namely PI turnover, IP3, release, CA+2 flux and receptor
aggregation. This may reveal differences in the potency by which
second messengers are generated, for instance between lectins
and anti-T3 M.Ab. The influence of chemical modulators/drugs on
these processes will also be examined. The signal transducing role
of receptor related G-binding proteins will be investigated in
terms of their potential for stimulating both adenylate cyclase
and phospholipase C activities. The importance of in vivo
autophosphorylation, translocation and proteolytic activation of
C-kinase will be addressed. Finally, the important interaction of
C-kinase with the tyrosine kinase, pp56 Tck, will be studied with a
view to understanding the possible link between membrane
phospholipid metabolism and mitogenic events.
In order to perform these studies, the following methodology has
been developed: protein phosphorylation studies,
immunoprecipitation of specific phosphorylated substrates, SDS-
PAGE and autoradiography, phospho-amino acid analysis, TLC of
phospholipid extracts, ion exchange chromatography to measure
IP3 release and cytoplasmic dot-blot analysis for mRNA. Intact
cell responses are monitored by flow cytometry, 3H-Td uptake,
IL-2 secretion and Quin 2 fluorescence.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10187533
-
项目类别:
-
资助金额:$55.31万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10058189
-
项目类别:
-
资助金额:$55.31万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10417161
-
项目类别:
-
资助金额:$52.93万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10654816
-
项目类别:
-
资助金额:$51.28万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
-
批准号:9186735
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2016
-
负责人:Andre Elias Nel
-
依托单位:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
-
批准号:9341321
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2016
-
负责人:Andre Elias Nel
-
依托单位:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
-
批准号:9769728
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2016
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8206804
-
项目类别:
-
资助金额:$39.36万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8464703
-
项目类别:
-
资助金额:$105.49万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8393965
-
项目类别:
-
资助金额:$7.56万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Administrative Core
-
批准号:8067636
-
项目类别:
-
资助金额:$6.89万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8605676
-
项目类别:
-
资助金额:$6.46万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8795269
-
项目类别:
-
资助金额:$2.28万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8147701
-
项目类别:
-
资助金额:$109.06万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8274480
-
项目类别:
-
资助金额:$107.03万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Project 2: Relating ENM Physicochemical Properties to Mechanism-Based Pulmonary T
-
批准号:8067631
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8537555
-
项目类别:
-
资助金额:$4.52万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8410038
-
项目类别:
-
资助金额:$36.93万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8605860
-
项目类别:
-
资助金额:$38.05万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:7795767
-
项目类别:
-
资助金额:$42.07万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
海外基金